Longeveron Inc. (LGVN), on Thursday, announced a positive outcome from its Type B meeting with the U.S. FDA, confirming the regulatory pathway for its investigational cell therapy, laromestrocel (Lomecel-B), as a potential treatment for Alzheimer's disease.
The planned Phase 2/3 pivotal trial will serve as the basis for Biological License Application or BLA submission, pending positive results.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.